Mundipharma licenses Starpharma’s VivaGel® BV

3 May 2018

Melbourne, Australia: Starpharma (ASX: SPL, OTCQX: SPHRY) and Mundipharma today announced they have signed a multi-region licence for the sales and marketing rights to VivaGel® BV in Asia (including China, Japan and Korea), the Middle East, Africa and the majority of Latin America.

Key points:

  • Mundipharma licenses Starpharma’s VivaGel® BV for Asia, Middle East, Africa and the majority of Latin America, to be marketed as part of the popular BETADINE® Feminine Care portfolio
  • Mundipharma is a leading global pharmaceutical company and owns the successful international brand - BETADINE®
  • BETADINE® has a market leading position in Feminine Care, trusted by women globally
  • Mundipharma will commence regulatory activities in their licensed territory immediately to secure expedited launch of VivaGel® BV
  • Deal terms include milestones of ~A$12.2 million and a revenue share

 

Read more

 

 

© Starpharma Holdings Limited 2017